Overview: Edarbi 40mg contains Azilsartan Medoxomil, a potent, long-acting Angiotensin II Receptor Blocker (ARB). It provides physiological support for the management of hypertension by selectively blocking the action of Angiotensin II, a hormone that causes blood vessels to constrict, thereby allowing for sustained vasodilation and reduced blood pressure.

Dosage & Administration

• Dosage: 1 tablet (40mg) per administration.
• Frequency: Once daily.
• Method: Administer orally with 200ml of water. Swallow the tablet whole; do not crush or chew.
• Timing: Can be taken with or without food.
• Consistency: For optimal results, take the medication at the same time each day to maintain a steady concentration in the bloodstream.

Technical Profile

• Primary Active: Azilsartan Medoxomil (40mg).
• Drug Class: Angiotensin II Receptor Blocker (ARB).
• Mechanism of Action: Azilsartan Medoxomil is a prodrug that is rapidly converted to its active moiety, azilsartan. It selectively binds to the $AT_1$ receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of Angiotensin II.
• Pharmacodynamics: Azilsartan binds more tightly to the $AT_1$ receptor and dissociates more slowly than other ARBs (like Valsartan or Olmesartan), providing robust 24-hour blood pressure control.

Safety & Storage

• Contraindications: Strictly contraindicated during pregnancy as it can cause serious injury or death to the developing fetus. Do not use in patients with severe renal impairment who are also taking Aliskiren.
• Storage: Store at controlled room temperature below 30°C. Keep in the original container to protect from light and moisture.
• Warning: Use with caution in patients with volume or salt depletion (e.g., those on high-dose diuretics), as this may lead to symptomatic hypotension. Monitor renal function and serum potassium levels periodically.